To validate our CEACAM5 observations, we used batch-corrected RNA-seq data derived from The Cancer Genome Atlas (TCGA) Pan-Cancer Initiative11 from normal tissue, primary tumor tissue, and metastatic or recurrent tumor tissue. This evidence concerns the gene CEACAM5 and neoplasm.